Cadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 3,666 Shares

by · The Cerbat Gem

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) CEO Quang Pham sold 3,666 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $3.58, for a total transaction of $13,124.28. Following the sale, the chief executive officer owned 132,715 shares in the company, valued at approximately $475,119.70. This trade represents a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cadrenal Therapeutics Price Performance

Shares of Cadrenal Therapeutics stock traded down $0.37 during trading on Monday, hitting $3.33. 67,393 shares of the stock were exchanged, compared to its average volume of 66,405. The firm’s 50-day moving average price is $5.01 and its 200 day moving average price is $6.59. The stock has a market cap of $9.56 million, a price-to-earnings ratio of -0.59 and a beta of 1.60. Cadrenal Therapeutics, Inc. has a 12-month low of $3.27 and a 12-month high of $14.64.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.47. As a group, research analysts forecast that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new stake in Cadrenal Therapeutics in the third quarter valued at approximately $103,000. Citadel Advisors LLC purchased a new stake in Cadrenal Therapeutics in the third quarter worth $274,000. Geode Capital Management LLC grew its stake in Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after purchasing an additional 1,818 shares during the period. Finally, DRW Securities LLC purchased a new stake in Cadrenal Therapeutics in the fourth quarter worth $171,000. Institutional investors and hedge funds own 7.92% of the company’s stock.

Analyst Ratings Changes

CVKD has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Monday, April 20th. Wall Street Zen raised shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, HC Wainwright dropped their target price on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $13.00.

Get Our Latest Report on Cadrenal Therapeutics

Cadrenal Therapeutics Company Profile

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

See Also